Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Livingwell Medical Center accepts most major insurance plans but also offers affordable self-pay rates for patients without ...

Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...

Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

While ChatGPT consistently produced responses that were factually correct in many cases, experts unanimously agreed that the ...

Singer Meghan Trainor has finally confirmed what fans have been speculating about for months—her dramatic weight loss wasn’t ...